Leiomyosarcoma medical therapy

Jump to navigation Jump to search

Leiomyosarcoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Leiomyosarcoma from other Diseases

Epidemiology and Demographics

Risk Factors

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Chest X Ray

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Leiomyosarcoma medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Leiomyosarcoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Leiomyosarcoma medical therapy

CDC on Leiomyosarcoma medical therapy

Leiomyosarcoma medical therapy in the news

Blogs on Leiomyosarcoma medical therapy

Directions to Hospitals Treating Leiomyosarcoma

Risk calculators and risk factors for Leiomyosarcoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Nima Nasiri, M.D.[2]

Overview

Uterine leiomyosarcoma (LMS) is the most common sarcoma arising from the uterus and comprises approximately 2% of uterine cancers. Patients diagnosed with LMS have a 5-year overall survival ranging from 25-75% . The primary management of LMS is hysterectomy. Adjuvant pelvic radiotherapy has been shown to improve local control and survival of patients with leiomyosarcoma.

Chemotherapy

  • Chemotherapy is recommended for individuals who have locally advanced, metastatic, or recurrent disease. Usually in combination with surgical procedures and/or radiation. The treatment is to use drugs to stop the growth of cancer cells either by killing the cells or by stopping them from dividing.[1][2][3]
  • Anthracyclines stops the tumor growth by different mechanism such as intercalating into deoxyribonucleic acid (DNA), blocking DNA and ribonucleic acid (RNA) synthesis, also causing DNA breakage by interfering with topoisomerase II activity.
  • Most common drugs used as first line treatment of soft tissue sarcoma include combination of ifosfamide and doxorubicin (Adriamycin).
  • Surgical resection of localized disease is a mainstay therapeutic strategy.
  • In the event tumors have metastasized or spread beyond uterus and not resectable by surgery, cytotoxic chemotherapeutic agents can be used in combination with radiation therapy.
  • Some of these chemotherapeutic agents are gemcitabine, docetaxel, ifosfamide, temozolomide, trabectedin, eribulin.

Radiation Therapy

Radiation therapy may be a useful adjunct to improve local control or where a cancer is inoperable due to the specific location or possible progression of the malignancy. It can be used postoperative to help treat known or possible residual disease.Radiation therapy can also be used as a palliative care in cases where extensive metastasis has already occurred.[4]

  • Adjuvant pelvic radiotherapy has been shown by some to improve disease-free survival. [5]
  • Studies had shown that there is a 38% disease-free survival rate in women receiving adjuvant radiotherapy compared with 18% in women receiving surgery alone.[6]

Palliative treatment

  • Palliative treatment: This treatment is used for the patients whose cancer has spread. It may improve the patient's quality of life by controlling the symptoms and complications of this disease.

References

  1. In, Gino K.; Hu, James S.; Tseng, William W. (2017). "Treatment of advanced, metastatic soft tissue sarcoma: latest evidence and clinical considerations". Therapeutic Advances in Medical Oncology. 9 (8): 533–550. doi:10.1177/1758834017712963. ISSN 1758-8340.
  2. Blay JY (2018) Getting up-to-date in the management of soft tissue sarcoma. Future Oncol 14 (10s):3-13. DOI:10.2217/fon-2018-0074 PMID: 29768050
  3. (1969) New antiviral drug. Nature 222 (5190):218. PMID: 5778386
  4. Reed NS, Mangioni C, Malmström H, Scarfone G, Poveda A, Pecorelli S et al. (2008) Phase III randomised study to evaluate the role of adjuvant pelvic radiotherapy in the treatment of uterine sarcomas stages I and II: an European Organisation for Research and Treatment of Cancer Gynaecological Cancer Group Study (protocol 55874). Eur J Cancer 44 (6):808-18. DOI:10.1016/j.ejca.2008.01.019 PMID: 18378136
  5. Harry, Vanessa N; Narayansingh, Gordon V; Parkin, David E (2007). "Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls". The Obstetrician & Gynaecologist. 9 (2): 88–94. doi:10.1576/toag.9.2.088.27309. ISSN 1467-2561.
  6. Harry, Vanessa N; Narayansingh, Gordon V; Parkin, David E (2007). "Uterine leiomyosarcomas: a review of the diagnostic and therapeutic pitfalls". The Obstetrician & Gynaecologist. 9 (2): 88–94. doi:10.1576/toag.9.2.088.27309. ISSN 1467-2561.


Template:WikiDoc Sources